Targeting Multiple Kinases to Treat Experimental Spinal Cord Injury.
Targeting Multiple Kinases to Treat Experimental Spinal Cord Injury.
批准号:
10393353
负责人:
John L Bixby
金额:
$1.68万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-07-01 至 2023-04-30
关键词:
AxonBiological AssayCatalytic DomainCell physiologyCellsContusionsCorticospinal TractsDevelopmentDorsalFailureForelimbFutureGrowthIn VitroIndividualInformation TheoryInjuryMachine LearningMediatingModelingMolecular TargetMotorNatural regenerationNerveNeuritesNeuronsOutcomePharmaceutical PreparationsPhosphotransferasesProcessRecovery of FunctionSignal TransductionSiteSmall Interfering RNASourceSpinal cord injurySpinal cord injury patientsTestingTherapeuticTransducersViral VectorWalkingaxon growthaxonal sproutingbehavioral outcomecentral nervous system injuryclinically relevantdrug discoveryeffective therapyexperienceexperimental studygraspimprovedin vivoin vivo Modelinhibitor/antagonistkinase inhibitorknock-downlight microscopynovelsmall moleculetargeted agent
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Spinal cord injury (SCI) patients experience limited functional recovery, owing in part to the paucity of axon
regrowth from injured CNS neurons. Effective treatments are lacking, likely because of multiple factors, intrinsic
and extrinsic, that inhibit axon growth. Thus, we require agents that target more than one source of regeneration
failure. Kinases are ubiquitous signal transducers that regulate most cellular processes, including axon growth.
To begin to identify compounds that positively regulate axon growth, we screened 1600 small-molecule kinase
inhibitors (KIs) in an in vitro CNS neurite outgrowth assay and identified “hit” KIs that reproducibly and strongly
promote outgrowth. Due to homology of catalytic domains, KIs typically inhibit multiple kinases. This makes it
difficult to identify the kinase(s) that mediate a KI’s effects on cells. We used information theory and machine
learning to analyze the inhibition profiles of KIs in relation to their effects on neurite outgrowth. This enabled us
to identify, and later validate via siRNA knockdown in primary neurons, multiple kinase targets (i.e. kinases that
should be inhibited to promote neurite outgrowth). These included previously known targets that regulate intrinsic
and extrinsic inhibitor factors, in addition to several novel candidates. Conversely, we identified kinases whose
activity is critical for neurite outgrowth, and whose inhibition must be avoided (anti-targets). We discovered
several KIs that inhibit multiple targets and no anti-targets. These KIs strongly promoted neurite outgrowth in
vitro. We tested the KI, RO48, that had the largest effect in vitro in two in vivo models. Our preliminary
experiments indicate that RO48 is remarkably effective in vivo. It promoted robust axonal growth of the
corticospinal tract (CST) in three separate models of CST injury (pyramidotomy, funiculotomy, dorsal
hemisection), and in the dorsal hemisection model, improved forelimb function. We propose to build on these
remarkable results to test the working hypothesis that the simultaneous inhibition of RO48’s five target kinases
(ROCK, PKC, PRKG1, PRKX, and RPS6K) promotes sprouting and regeneration of CST axons. This will be
accomplished using viral vectors to knock down expression of the different target kinases individually and in
combination. We will do knockdown in CST neurons in the cortex. We will assess CST axon growth at the injury
site using light microscopy. We will also perform experiments to determine if RO48-induced CST axon growth
promotes axon sprouting, regeneration, or both, and whether RO48 improves behavioral outcomes such as
grasping and walking after a contusion injury.These experiments will 1) validate novel kinases as in vivo targets
for future development of SCI therapeutics 2) determine whether these kinases regulate CST axon sprouting,
regeneration, or both, and 3) confirm whether the substantial stimulation of axon growth induced by treatment
with RO48 improves motor outcomes in a clinically relevant contusion model.
期刊论文(9)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
AAV8 transduction capacity is reduced by prior exposure to endosome-like pH conditions.
通过事先暴露于内体样pH条件来降低AAV8转导能力。
DOI:
10.4103/1673-5374.299272
发表时间:
2021-05
期刊:
Neural regeneration research
影响因子:
6.1
作者:
[Lowell JA, Mah KM, Bixby JL, Lemmon VP]
通讯作者:
Lemmon VP
DOI:
10.1177/2472555220930697
发表时间:
2020-08
期刊:
SLAS discovery : advancing life sciences R & D
影响因子:
--
作者:
[Devkota P, Danzi MC, Lemmon VP, Bixby JL, Wuchty S]
通讯作者:
Wuchty S
DOI:
10.1016/j.expneurol.2022.114117
发表时间:
2022-09
期刊:
EXPERIMENTAL NEUROLOGY
影响因子:
5.3
作者:
[Mah, Kar Men, Wu, Wei, Al-Ali, Hassan, Sun, Yan, Han, Qi, Ding, Ying, Munoz, Melissa, Xu, Xiao-Ming, Lemmon, Vance P., Bixby, John L.]
通讯作者:
Bixby, John L.
DOI:
10.1177/24725552211026270
发表时间:
2021-12
期刊:
SLAS DISCOVERY
影响因子:
3.1
作者:
[Lowell, Jeffrey A., O'Neill, Nicholas, Danzi, Matt C., Al-Ali, Hassan, Bixby, John L., Lemmon, Vance P.]
通讯作者:
Lemmon, Vance P.
DOI:
10.1371/journal.pone.0201321
发表时间:
2018
期刊:
PloS one
影响因子:
3.7
作者:
[Strang BL, Asquith CRM, Moshrif HF, Ho CM, Zuercher WJ, Al-Ali H]
通讯作者:
Al-Ali H
Targeting Multiple Kinases to Treat Experimental Spinal Cord Injury
-
批准号:9917854
-
项目类别:
-
资助金额:$46.55万
-
财政年份:2017
-
负责人:John L Bixby
-
依托单位:
Targeting Multiple Kinases to Treat Experimental Spinal Cord Injury
-
批准号:10160972
-
项目类别:
-
资助金额:$46.55万
-
财政年份:2017
-
负责人:John L Bixby
-
依托单位:
Regenbase: A Searchable Database to Organize Regeneration Knowledge via Ontologie
-
批准号:8465934
-
项目类别:
-
资助金额:$55.02万
-
财政年份:2012
-
负责人:John L Bixby
-
依托单位:
Regenbase: A Searchable Database to Organize Regeneration Knowledge via Ontologie
-
批准号:8653627
-
项目类别:
-
资助金额:$56.44万
-
财政年份:2012
-
负责人:John L Bixby
-
依托单位:
Regenbase: A Searchable Database to Organize Regeneration Knowledge via Ontologie
-
批准号:8365739
-
项目类别:
-
资助金额:$60.38万
-
财政年份:2012
-
负责人:John L Bixby
-
依托单位:
Regenbase: A Searchable Database to Organize Regeneration Knowledge via Ontologie
-
批准号:8839677
-
项目类别:
-
资助金额:$57.01万
-
财政年份:2012
-
负责人:John L Bixby
-
依托单位:
Triazine-based compounds to promote regeneration in optic neuropathies
-
批准号:8284307
-
项目类别:
-
资助金额:$3.28万
-
财政年份:2011
-
负责人:John L Bixby
-
依托单位:
Triazine-based compounds to promote regeneration in optic neuropathies
-
批准号:8128170
-
项目类别:
-
资助金额:$19.68万
-
财政年份:2011
-
负责人:John L Bixby
-
依托单位:
Novel Compounds That Overcome Glial Inhibition of Axonal Regeneration
-
批准号:8394926
-
项目类别:
-
资助金额:$31.65万
-
财政年份:2009
-
负责人:John L Bixby
-
依托单位:
Novel Compounds That Overcome Glial Inhibition of Axonal Regeneration
-
批准号:7582047
-
项目类别:
-
资助金额:$33.07万
-
财政年份:2009
-
负责人:John L Bixby
-
依托单位:
Novel Compounds That Overcome Glial Inhibition of Axonal Regeneration
-
批准号:7848703
-
项目类别:
-
资助金额:$4.46万
-
财政年份:2009
-
负责人:John L Bixby
-
依托单位:
Novel Compounds That Overcome Glial Inhibition of Axonal Regeneration
-
批准号:7752485
-
项目类别:
-
资助金额:$33.13万
-
财政年份:2009
-
负责人:John L Bixby
-
依托单位:
Novel Compounds That Overcome Glial Inhibition of Axonal Regeneration
-
批准号:7991788
-
项目类别:
-
资助金额:$32.8万
-
财政年份:2009
-
负责人:John L Bixby
-
依托单位:
Novel Compounds That Overcome Glial Inhibition of Axonal Regeneration
-
批准号:8065240
-
项目类别:
-
资助金额:$6.89万
-
财政年份:2009
-
负责人:John L Bixby
-
依托单位:
Novel Compounds That Overcome Glial Inhibition of Axonal Regeneration
-
批准号:8204614
-
项目类别:
-
资助金额:$32.8万
-
财政年份:2009
-
负责人:John L Bixby
-
依托单位:
Novel Gene Targets for CNS Axonal Regeneration
-
批准号:9093811
-
项目类别:
-
资助金额:$46.58万
-
财政年份:2007
-
负责人:John L Bixby
-
依托单位:
Novel Gene Targets for CNS Axonal Regeneration
-
批准号:8827566
-
项目类别:
-
资助金额:$47.05万
-
财政年份:2007
-
负责人:John L Bixby
-
依托单位:
Novel Gene Targets for CNS Axonal Regeneration
-
批准号:8931007
-
项目类别:
-
资助金额:$45.88万
-
财政年份:2007
-
负责人:John L Bixby
-
依托单位:
PREDOCTORAL TRAINING PROGRAM IN THE NEUROSCIENCES
-
批准号:6313974
-
项目类别:
-
资助金额:$14.9万
-
财政年份:2001
-
负责人:John L Bixby
-
依托单位:
Predoctoral Training Program in the Neurosciences
-
批准号:7066936
-
项目类别:
-
资助金额:$18.25万
-
财政年份:2001
-
负责人:John L Bixby
-
依托单位:
海外基金